Food and Drug Administration ruling will increase development costs for lab tests, but some entrepreneurs and investors welcome the shift. Startup PrognomiQ is developing and expects to seek regulatory approval for a test for early lung cancer.
Read the full article on WSJ Pro: Venture Capital here.
